Biliary excretion of ximelagatran and its metabolites and the influence of erythromycin following intraintestinal administration to healthy volunteers

Journal of Clinical Pharmacology

Volumn 51, Issue 5, 2011, Pages 770-783

  Matsson, Elin M ^a   Eriksson, Ulf G ^c   Knutson, Lars ^b   Hoffmann, Kurt Jürgen ^c   Logren, Ulrika ^c   Fridblom, Patrik ^b   Petri, Niclas ^a,d   Lennernäs, Hans ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d Ferring Pharmaceuticals AS   (Denmark)

Author keywords

biliary clearance; drug interactions; erythromycin; thrombin inhibitor; ximelagatran

Indexed keywords

ERYTHROMYCIN; ERYTHROMYCIN STEARATE; MACROGOL 4000; MELAGATRAN; XIMELAGATRAN;

ADULT; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BILIARY EXCRETION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BILE LEVEL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG METABOLISM; DUODENUM BIOPSY; FEMALE; HUMAN; HUMAN EXPERIMENT; LIMIT OF QUANTITATION; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; NORMAL HUMAN; RAT; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; ANTI-BACTERIAL AGENTS; ANTITHROMBINS; AREA UNDER CURVE; AZETIDINES; BENZYLAMINES; BILE; BIOTRANSFORMATION; CROSS-OVER STUDIES; DUODENUM; ERYTHROMYCIN; FEMALE; HALF-LIFE; HUMANS; INTUBATION, GASTROINTESTINAL; MALE; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; SWEDEN; YOUNG ADULT;

EID: 79955527157     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010370975     Document Type: Article

References (40)

1. Zamek-Gliszczynski MJ, Hoffmaster KA, Nezasa K, Tallman MN, Brouwer KL. Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. Eur J Pharm Sci. 2006 ; 27: 447-486 (Pubitemid 43363339)
2. Keppler D, Konig J. Hepatic secretion of conjugated drugs and endogenous substances. Semin Liver Dis. 2000 ; 20: 265-272
3. Bergman E, Forsell P, Tevell A, et al. Biliary secretion of rosuvastatin and bile acids in humans during the absorption phase. Eur J Pharm Sci. 2006 ; 29: 205-214 (Pubitemid 44602407)
4. Ryde M, Gustavsson S. Biliary excretion of olsalazine sodium in humans. Eur J Drug Metab Pharmacokinet. 1987 ; 12: 17-24 (Pubitemid 17120677)
5. Lundahl A, Hedeland M, Bondesson U, Knutson L, Lennernas H. The effect of St. John's wort on the pharmacokinetics, metabolism and biliary excretion of finasteride and its metabolites in healthy men. Eur J Pharm Sci. 2009 ; 36: 433-443
6. Agnelli G, Eriksson BI, Cohen AT, et al. Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran. Thromb Res. 2009 ; 123: 488-497
7. Lee WM, Larrey D, Olsson R, et al. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf. 2005 ; 28: 351-370 (Pubitemid 40545769)
8. Edling Y, Sivertsson L, Andersson TB, Porsmyr-Palmertz M, Ingelman-Sundberg M. Pro-inflammatory response and adverse drug reactions: mechanisms of action of ximelagatran on chemokine and cytokine activation in a monocyte in vitro model. Toxicol In Vitro. 2008 ; 22: 1588-1594
9. Kenne K, Skanberg I, Glinghammar B, et al. Prediction of drug-induced liver injury in humans by using in vitro methods: The case of ximelagatran. Toxicol In Vitro. 2008 ; 22: 730-746
10. Gustafsson D, Nystrom J, Carlsson S, et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res. 2001 ; 101: 171-181 (Pubitemid 32176022)
11. Clement B, Lopian K. Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug. Drug Metab Dispos. 2003 ; 31: 645-651 (Pubitemid 36444174)
12. Eriksson UG, Bredberg U, Hoffmann KJ, et al. Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Metab Dispos. 2003 ; 31: 294-305
13. Andersson S, Hofmann Y, Nordling A, et al. Characterization and partial purification of the rat and human enzyme systems active in the reduction of N-hydroxymelagatran and benzamidoxime. Drug Metab Dispos. 2005 ; 33: 570-578 (Pubitemid 40393201)
14. Clement B, Mau S, Deters S, Havemeyer A. Hepatic, extrahepatic, microsomal, and mitochondrial activation of the N-hydroxylated prodrugs benzamidoxime, guanoxabenz, and Ro 48-3656 ([[1-[(2s)-2-[[4-[(hydroxyamino) iminomethyl]benzoyl]amino]-1-oxopropyl]-4-piperidinyl]oxy]-acetic acid). Drug Metab Dispos. 2005 ; 33: 1740-1747
15. Reh R, Ozols J, Clement B. Involvement of stearoyl-CoA desaturase in the reduction of amidoxime prodrugs. Xenobiotica. 2008 ; 38: 1177-1190
16. Gruenewald S, Wahl B, Bittner F, et al. The fourth molybdenum containing enzyme mARC: cloning and involvement in the activation of N-hydroxylated prodrugs. J Med Chem. 2008 ; 51: 8173-8177
17. Sjodin E, Fritsch H, Eriksson UG, et al. Intestinal and hepatobiliary transport of ximelagatran and its metabolites in pigs. Drug Metab Dispos. 2008 ; 36: 1519-1528
18. Eriksson UG, Dorani H, Karlsson J, et al. Influence of erythromycin on the pharmacokinetics of ximelagatran may involve inhibition of P-glycoprotein-mediated excretion. Drug Metab Dispos. 2006 ; 34: 775-782
19. Bredberg E, Andersson TB, Frison L, et al. Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions. Clin Pharmacokinet. 2003 ; 42: 765-777 (Pubitemid 36976123)
20. Duner K, Backstrom J, Magnell N, Svennberg H, Ahnoff M, Logren U. Determination of ximelagatran, melagatran and two intermediary metabolites in plasma by mixed-mode solid phase extraction and LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 ; 852: 317-324 (Pubitemid 46830126)
21. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev. 1998 ; 50: 387-412
22. Clarke's Analysis of Drugs and Poisons. 3 rd ed Moffat AC Osselton MD Widdop B, ed. London: The Pharmaceutical Press ; 2004 :
23. Somogyi AA, Bochner F, Hetzel D, Williams DB. Evaluation of the intestinal absorption of erythromycin in man: absolute bioavailability and comparison with enteric coated erythromycin. Pharm Res. 1995 ; 12: 149-154
24. Dette GA, Knothe H, Herrmann G. Erythromycin binding to human serum. Biochem Pharmacol. 1982 ; 31: 1081-1087 (Pubitemid 12147952)
25. Ghibellini G, Leslie EM, Brouwer KL. Methods to evaluate biliary excretion of drugs in humans: an updated review. Mol Pharm. 2006 ; 3: 198-211 (Pubitemid 44021428)
26. Li N, Zhang Y, Hua F, Lai Y. Absolute difference of hepatobiliary transporter multidrug resistance-associated protein (MRP2/Mrp2) in liver tissues and isolated hepatocytes from rat, dog, monkey, and human. Drug Metab Dispos. 2009 ; 37: 66-73
27. Lave T, Portmann R, Schenker G, et al. Interspecies pharmacokinetic comparisons and allometric scaling of napsagatran, a low molecular weight thrombin inhibitor. J Pharm Pharmacol. 1999 ; 51: 85-91 (Pubitemid 29097274)
28. Mahmood I. Interspecies scaling of biliary excreted drugs: a comparison of several methods. J Pharm Sci. 2005 ; 94: 883-892 (Pubitemid 40577320)
29. Fagerholm U. Prediction of human pharmacokinetics-biliary and intestinal clearance and enterohepatic circulation. J Pharm Pharmacol. 2008 ; 60: 535-542 (Pubitemid 351589043)
30. Catnach SM, Fairclough PD, Trembath RC, et al. Effect of oral erythromycin on gallbladder motility in normal subjects and subjects with gallstones. Gastroenterology. 1992 ; 102: 2071-2076
31. Wehrmann T, Pfeltzer C, Caspary WF. Effect of erythromycin on human biliary motility. Aliment Pharmacol Ther. 1996 ; 10: 421-426 (Pubitemid 26173891)
32. Medhus AW, Bondi J, Gaustad P, Husebye E. Low-dose intravenous erythromycin: effects on postprandial and fasting motility of the small bowel. Aliment Pharmacol Ther. 2000 ; 14: 233-240 (Pubitemid 30088301)
33. Nissan A, Freund HR, Hanani M. Direct inhibitory effect of erythromycin on human alimentary tract smooth muscle. Am J Surg. 2002 ; 183: 413-418 (Pubitemid 34442506)
34. Seithel A, Eberl S, Singer K, et al. The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab Dispos. 2007 ; 35: 779-786 (Pubitemid 46641549)
35. Kobayashi Y, Sakai R, Ohshiro N, Ohbayashi M, Kohyama N, Yamamoto T. Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver. Drug Metab Dispos. 2005 ; 33: 619-622 (Pubitemid 40593874)
36. Eberl S, Renner B, Neubert A, et al. Role of P-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies. Clin Pharmacokinet. 2007 ; 46: 1039-1049 (Pubitemid 350136910)
37. Yamano K, Yamamoto K, Kotaki H, et al. Quantitative prediction of metabolic inhibition of midazolam by erythromycin, diltiazem, and verapamil in rats: implication of concentrative uptake of inhibitors into liver. J Pharmacol Exp Ther. 2000 ; 292: 1118-1126 (Pubitemid 30136609)
38. Darnell M, Karlsson JE, Owen A, et al. Investigation of the involvement of P-glycoprotein and multidrug resistance-associated protein 2 in the efflux of ximelagatran and its metabolites by using short hairpin RNA knockdown in Caco-2 cells. Drug Metab Dispos. 2010 ; 38: 491-497.
39. Dorani H, Schutzer KM, Sarich TC, et al. Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran co-administered with different classes of antibiotics in healthy volunteers. Eur J Clin Pharmacol. 2007 ; 63: 571-581 (Pubitemid 46684489)
40. Teng R, Sarich TC, Eriksson UG, et al. A pharmacokinetic study of the combined administration of amiodarone and ximelagatran, an oral direct thrombin inhibitor. J Clin Pharmacol. 2004 ; 44: 1063-1071 (Pubitemid 39096821)